Embryonic ectoderm development (EED) (EED)

Embryonic ectoderm development (EED) is a core non-catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), which is a major epigenetic regulator responsible for the trimethylation of histone H3 at lysine 27 (H3K27me3) (UniProt P48332). EED acts as a molecular reader that recognizes and binds to existing H3K27me3 marks through its WD40 repeat domain, a process that allosterically activates the catalytic subunit EZH2 and promotes the propagation of repressive chromatin states (NIH, 1.3.1). This function is critical for maintaining gene silencing patterns during embryonic development, cell differentiation, and the preservation of stem cell pluripotency (Wikipedia, 1.2.3). Dysregulation or overexpression of EED is implicated in various cancers, particularly B-cell lymphomas and myeloid leukemias, where it contributes to the silencing of tumor suppressor genes (NIH, 1.3.1). Additionally, germline mutations in EED are associated with rare overgrowth disorders such as Cohen-Gibson syndrome (GeneCards, 1.2.4). Therapeutic targeting of EED has emerged as a promising strategy to inhibit PRC2 activity, especially in cases where traditional EZH2 inhibitors face resistance or limited efficacy (NIH, 1.3.1). Allosteric EED inhibitors, such as MAK683 and APG-5918, bind to the H3K27me3-binding pocket of EED, disrupting the complex's allosteric activation and leading to a global reduction in H3K27me3 levels (NIH, 1.3.3). These inhibitors are currently being evaluated in clinical trials for their ability to reactivate silenced genes and suppress tumor growth in both hematological and solid malignancies (NIH, 1.3.5).

Other names

HWAIT1COGISPolycomb protein EEDWD repeat-containing protein EED

Allosteric inhibition of the Polycomb Repressive Complex 2 (PRC2) by binding to the H3K27me3-binding pocket of EED, which prevents the allosteric activation of the catalytic subunit EZH2 and leads to the reduction of H3K27me3 levels and destabilization of the complex.